COX-2s, Statins Have No Class In USP Medicare Draft Formulary
Executive Summary
U.S. Pharmacopeia has relegated some of the pharmaceutical industry's biggest blockbuster drug "classes" to the status of "recommended subdivisions" in its draft model Medicare formulary
You may also be interested in...
USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes
Proton pump inhibitors may be the only commercially significant group of drugs to gain "pharmacologic class" status in the revisions to U.S. Pharmacopeia's model guidelines for Medicare drug plans
USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes
Proton pump inhibitors may be the only commercially significant group of drugs to gain "pharmacologic class" status in the revisions to U.S. Pharmacopeia's model guidelines for Medicare drug plans
USP Responding To Congress’ Questions On Medicare Formulary Guidelines
The U.S. Pharmacopeia has been providing congressional committees with information as it moves toward finalizing its model formulary guidelines for the Medicare prescription drug benefit